ACTU on XNAS, Health Care, Actuate Therapeutics, Inc., job postings
Measures activity, not value. Not investment advice.
Shares down 96% in a year as institutional holders fell 37% and a delisting notice arrived.
BadThree share registrations (S-1) filed in 90 days, adding shares
WatchCompanies filing S-1s trailed their sector by 23.8 points over 6 months
Written by AI from the data on this page, 22 Nov 2026. Not investment advice.
Profile and fundamentals
From its SEC filings, 12 months to 30 Sep 2026
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
Revenue and net income per quarter. Quarter to 30 Sep 2026: net loss $3.4M.
31 Mar 2023RevenueNet incomeNet losstallest bar $8.3M30 Sep 2026
See the numbers
Quarter to
Revenue
Net income
30 Sep 2026
–
-$3.4M
30 Jun 2026
–
-$4.9M
31 Mar 2026
–
-$5.6M
31 Dec 2025
–
-$4.6M
30 Sep 2025
–
-$5.4M
30 Jun 2025
–
-$5.9M
31 Mar 2025
–
-$6.3M
31 Dec 2024
–
-$6.4M
30 Sep 2024
–
-$6.0M
30 Jun 2024
–
-$6.6M
31 Mar 2024
–
-$8.3M
31 Dec 2023
–
-$7.6M
30 Sep 2023
–
-$6.3M
30 Jun 2023
–
-$5.5M
31 Mar 2023
–
-$5.3M
Fundamentals, 12 months to 30 Sep 2026
Measure
Latest
Year before
Peer median
RevenueiSales over the last 12 months reported.
–
–
Revenue growthiRevenue of the last 12 months compared with the 12 months before.
–
+11%
Net incomeiProfit after all costs and taxes over the last 12 months reported. Negative is a loss.
-$18.5M
-$24.1M
EPS (diluted)iEarnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split).
–
–
Gross marginiWhat is left of each dollar of sales after the direct cost of making the product or service.
–
–
73.2%
Operating marginiOperating income as a share of sales: profit from the business before interest and taxes.
–
–
-25.0%
Net marginiNet income as a share of sales: what the owners keep of each dollar sold.
–
–
-18.2%
Return on equityiNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money.
–
-58.8%
Free cash flowiCash from operations minus capital spending over the last 12 months: cash the business produced.
–
–
CashiCash, cash equivalents and short-term investments on the latest balance sheet.
$2.1M
$16.9M
DebtiShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted.
$405K
–
Net debtiDebt minus cash. Negative means the company holds more cash than it owes (net cash).
-$1.7M (net cash)
–
Debt to equityiDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative.
–
0.0
Book value per shareiShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding.
–
P/EiPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss.
loss
19.3
P/SiPrice to sales: market cap divided by revenue of the last 12 months.
–
5.0
EV/SalesiEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months.
–
5.0
P/BiPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative.
–
2.0
Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.
Peers nearest by market cap, its own industry first
Insider buy/sell iShares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.
+$50K
bought $50K, sold $0
Institutional holders iThe number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.
-37%
41 13F filers vs 65
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
22%
13.3M shares held by 13F filers (30 Sep 2026) of 60.4M outstanding (13 Nov 2026)
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
2.2%
1.3M shares sold short (30 Oct 2026) of 60.4M outstanding (13 Nov 2026)
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
2.1
1.3M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
-30%
1.9M shares sold short in the report before, 1.3M on 30 Oct 2026
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
44%
44% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 51%
News iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
13
13 articles in the last 7 days; its usual week has 3 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
4.3×
13 articles in the last 7 days; its usual week has 3.
Unusual now sharp changes in the last 90 days, compared with its own past
Short interest 1.9M, 3.3× a year earlier
Price $0.23 on 20 Nov 2026, -96% over 12 months (12-month range $0.21 to $7.63)
Sharp change
8-K and other filings
Insider net buying (open market). Insiders sold a net $1.6M in the last 12 months (the 12 months before: $500K).Institutional holders (13F filers). 41 13F filers reported holding it in the latest 13F quarter, -4.7% on a year earlier.
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, revenue per quarter, capital spending per quarter, federal obligations, lobbying spend, workers in warn layoff notices.
Made public in the last 90 days: it had 1.9M shares sold short in the 15 Oct 2026 report, 3.3× the same report last year; it also had 1.2M shares sold short in the 31 Aug 2026 report, 2.1× the same report last year.
Short interest spike: had 1.9M shares sold short in the 15 Oct 2026 report, 3.3× the same report last year Public on 27 Oct 2026.
In 12 months: 3 share registrations, 2 major agreements, 2 delisting notices, 1 director or officer change. Results releases and routine reports are left out.
had 1.9M shares sold short in the 15 Oct 2026 report, 3.3× the same report last year.
Same report last year: 561K; its normal report is 661K.
See the evidence
This period
1.9M (the 15 Oct 2026 report)
Normal report (median of 24 earlier)
661K
Typical spread (median absolute deviation)
174K
How far from its usual level
+4.7
Same report last year
561K
History used
791 days
the 15 Oct 2026 report24 earlier reportsnormal: 661K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.2M shares sold short in the 31 Aug 2026 report, 2.1× the same report last year.
Same report last year: 549K; its normal report is 625K.
See the evidence
This period
1.2M (the 31 Aug 2026 report)
Normal report (median of 24 earlier)
625K
Typical spread (median absolute deviation)
94K
How far from its usual level
+3.9
Same report last year
549K
History used
746 days
the 31 Aug 2026 report24 earlier reportsnormal: 625K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 948K shares sold short in the 30 Apr 2026 report, 6.9× the same report last year.
Same report last year: 137K; its normal report is 551K.
See the evidence
This period
948K (the 30 Apr 2026 report)
Normal report (median of 24 earlier)
551K
Typical spread (median absolute deviation)
66K
How far from its usual level
+4.1
Same report last year
137K
History used
623 days
the 30 Apr 2026 report24 earlier reportsnormal: 551K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 915K shares sold short in the 15 Apr 2026 report, 7.0× the same report last year.
Same report last year: 130K; its normal report is 543K.
See the evidence
This period
915K (the 15 Apr 2026 report)
Normal report (median of 24 earlier)
543K
Typical spread (median absolute deviation)
72K
How far from its usual level
+3.5
Same report last year
130K
History used
608 days
the 15 Apr 2026 report24 earlier reportsnormal: 543K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 561K shares sold short in the 15 Oct 2025 report, 16× the same report last year.
Same report last year: 34K; its normal report is 115K.
See the evidence
This period
561K (the 15 Oct 2025 report)
Normal report (median of 24 earlier)
115K
Typical spread (median absolute deviation)
81K
How far from its usual level
+3.7
Same report last year
34K
History used
426 days
the 15 Oct 2025 report24 earlier reportsnormal: 115K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 615K shares sold short in the 30 Sep 2025 report, 47× the same report last year.
Same report last year: 13K; its normal report is 96K.
See the evidence
This period
615K (the 30 Sep 2025 report)
Normal report (median of 24 earlier)
96K
Typical spread (median absolute deviation)
63K
How far from its usual level
+5.6
Same report last year
13K
History used
411 days
the 30 Sep 2025 report24 earlier reportsnormal: 96K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 566K shares sold short in the 15 Sep 2025 report, 46× the same report last year.
Same report last year: 12K; its normal report is 89K.
See the evidence
This period
566K (the 15 Sep 2025 report)
Normal report (median of 24 earlier)
89K
Typical spread (median absolute deviation)
55K
How far from its usual level
+5.8
Same report last year
12K
History used
396 days
the 15 Sep 2025 report24 earlier reportsnormal: 89K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 549K shares sold short in the 29 Aug 2025 report, 73× the same report last year.
Same report last year: 7,561; its normal report is 83K.
See the evidence
This period
549K (the 29 Aug 2025 report)
Normal report (median of 24 earlier)
83K
Typical spread (median absolute deviation)
52K
How far from its usual level
+6.1
Same report last year
7,561
History used
379 days
the 29 Aug 2025 report24 earlier reportsnormal: 83K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 585K shares sold short in the 15 Aug 2025 report, 136× the same report last year.
Same report last year: 4,290; its normal report is 81K.
See the evidence
This period
585K (the 15 Aug 2025 report)
Normal report (median of 24 earlier)
81K
Typical spread (median absolute deviation)
53K
How far from its usual level
+6.5
Same report last year
4,290
History used
365 days
the 15 Aug 2025 report24 earlier reportsnormal: 81K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Showing the newest 40 of 44 entries; narrow the window or the kind of data to see older ones.
Not listed: 31 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it